American Board of Internal Medicine
MD, George Washington University
Residency, Internal Medicine
Long Island Jewish Medical Center
Mount Sinai Hospital
New York Magazine
Risk factors for chronic kidney disease
Expertise in the design of clinical trails is used to understand the clinical epidemiology and treatment of HIV-associated kidney disease. Other areas of clinical research include risk factors for cardiovascular disease in chronic kidney disease, outcomes in endstage renal disease and the prevalence and natural history of renal artery stenosis.
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease
The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy. The study is considered research because the study drug finerenone is under devel...
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care
The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy. The study is considered research because the study drug finerenone is u...
Winston JA, Burns GC, Klotman PE. Treatment of HIV-associated nephropathy. Semin Nephrol 2000; 20(3): 293-298.
Bruggeman LA, Ross MD, Tanji N, Cara S, Dikman RE, Gordon GC, Burns VD, D'Agati JA, Winston JA, Klotman ME, Klotman PE. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11(11): 2079-2087.
Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 2000; 14(12): 637-645.
Winston J, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, Klotman PE, Klotman ME. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001; 344(26): 1979-1984.
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68(3): 711-722.
Winston JA. Editorial comment: The increasing problem of HIV-Associated Nephropathy. AIDS Reader 2002 12:110-111.
Schwartz EJ, Neumann AU, Fierer DS, Keller MJ, Parkas V, Zhang DY, Klotman ME, Winston JA, Klotman PE. HIV-1 dynamics in haemodialysis patients. AIDS 2002; 14: 1301-1303.
Winston JA, Klotman PE. Renal Disease. In: Dolin R, Masur H, Saag M, editors. AIDS Therapy. 2nd New York, Churchill Livingston; 2003.
Szczech LA, Kalayjian R, Rodriguez R, Gupta S, Coladonato J, Winston J. The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis. Kidney Int 2003 Jun; 63(6): 2295-2300.
Farkouh ME, Robbins MJ, Urooj-Zafar M, Shimbo D, Davidson KW, Puttappa R, Winston J, Halperin JL, Epstein EM, Patel M, Talor Z, Chesebro JH. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med 2003 February; 114(3): 224-226.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Winston during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.